Thermo Fisher Cell And Gene Live Events

1. 2025 CGT Regulatory Outlook 1/23/2025

   As the cell and gene therapy landscape continues to rapidly evolve, with over 450 unique products in clinical development and 50 approvals expected by 2030, understanding the regulatory environment is crucial for stakeholders across the industry. Cell & Gene Live focused on the forward-looking perspectives on the regulatory landscape that will shape the future of cell and gene therapies. Watch now to hear what our distinguished speakers had to say on the matter.

2. Unlocking The Future Of Allogeneic Cell Therapy For Oncology 4/30/2024

   Hear from experts in the cell and gene therapy space about their shared insights into potential trends driving the future of allogeneic therapies for oncology.

3. 2024 Regulatory Outlook With FDA's Drs. Peter Marks And Nicole Verdun 1/25/2024

   Explore the evolving regulatory landscape for cell and gene therapies in 2024 including the increasing speed availability of cell and gene therapies by enabling manufacturing processes and standards development.

4. mRNA For Cancer Immunotherapy: 2024 Outlook 12/5/2023

   As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS.

5. Stability To Scalability: The Future Of Viral Vector Therapies 9/26/2023

   Despite advances that have contributed to improvements in viral vector yields, innovation is still needed in the CGT sector to impact product quality and accelerate scale for viral vector production.

6. Driving Down COGS: Automation's Role In Cell Therapy Manufacturing 7/11/2023

   Process automation, task automation, and test automation have become crucial components of cell therapy manufacturing. Improve your cell therapy manufacturing costs and scalability via standardization and automation.

7. Tackling Cell And Gene Therapies' Top 3 Regulatory Impediments 1/11/2023

   Listen in to this expert discussion on problems in the cell and gene therapy industry, specific FDA initiatives to overcome these, broader regulatory trends, and more.